ZLAB May 2024 15.000 call
| Previous Close | 2.2500 |
| Open | 1.9000 |
| Bid | 6.4000 |
| Ask | 9.1000 |
| Strike | 15.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 1.9000 - 2.2500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 190 |
Business WireZai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
SHANGHAI & CAMBRIDGE, Mass., May 13, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has approved the New Drug Application (NDA) for AUGTYRO™ (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer (NSCLC). The approval is based on the pivotal TRIDENT-1 study, an open-label, single-arm, Phase 1/2 trial that evaluated repotrectinib in TKI-naïv
Simply Wall St.Zai Lab Limited (NASDAQ:ZLAB) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Zai Lab Limited ( NASDAQ:ZLAB ) just released its first-quarter report and things are looking bullish. The results...
Insider MonkeyZai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call Transcript
Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call Transcript May 9, 2024 Zai Lab Limited isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, ladies and gentlemen, thank you for standing by and welcome to Zai Lab’s First Quarter 2024 […]
